Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Operational Other
confidence 75%
filed 2026-07-07
Item 1.02
The filing discloses termination of a material licensing agreement with CF Benchmarks for the CME CF Solana-Dollar Reference Rate, which is used daily to value the Trust's shares and calculate net asset value. The Sponsor is transitioning to FTSE as the new benchmark provider effective August 24, 2026. While this is a material operational change affecting the ETF's core valuation mechanism, it does not fit neatly into specific categories like debt_issuance, ma_activity, or covenant_breach; it is a strategic operational transition in benchmark provider that would affect investor assessment of the fund's operations.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-07
Item 1.02
The filing discloses termination of a material benchmark licensing agreement with CF Benchmarks (effective August 31, 2026) and transition to a new licensing agreement with FTSE International Limited. The Pricing Benchmark is used daily to value the Trust's shares and calculate net asset value, making this operational change material to the ETF's functioning. While Item 1.02 typically covers M&A terminations, this is a service provider transition affecting the Trust's core operational infrastructure rather than a business combination or acquisition termination.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-07
Evolution Metals announced execution of a supply contract with Senri Trading Co., Ltd. for neodymium-praseodymium (NdPr) metal from a non-China source to support its rare earth magnet production operations targeting 10,000 metric tons per annum. This is a material operational/strategic event—a significant supply agreement enabling the company's production expansion and compliance with upcoming DFARS 252.225-7052 restrictions on Chinese-origin rare earth magnets in U.S. defense systems (effective January 1, 2027). While not a merger, acquisition, or specific financial obligation, the supply contract is a critical operational milestone for the company's business strategy and capacity utilization.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-07-07
This 8-K discloses the consummation of a $230 million initial public offering by Viking Acquisition Corp. II on July 6, 2026, including entry into multiple material definitive agreements (underwriting agreement, warrant agreements, insider letter agreement, registration rights agreement, and indemnity agreements). While the primary event is an IPO capital raise, the filing is structured around Item 1.01 (Entry into Material Definitive Agreement) and Item 3.02 (Unregistered Sales of Equity Securities), which are financial/capital events. However, the core transaction—a blank-check SPAC raising capital to pursue a future business combination—is most appropriately classified as a material capital/financing event. The closest taxonomy fit is `ma_activity` given the material nature of the IPO and the company's stated purpose to effect a merger or business combination, though this is technically a capital raise rather than an M&A transaction itself.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-07
Item 5.02
Seth Demsey was appointed as co-Chief Executive Officer of Corvex, Inc., effective July 1, 2026, following the Annual Meeting. This appointment represents a material change in the Company's executive leadership.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-07-07
Item 5.07
Corvex held its Annual Meeting on July 1, 2026, with shareholders voting on seven matters: election of three directors (Jay Crystal, Patrick Fleury, and Nicholas Donofrio), approval of equity issuances related to a merger (Conversion Proposal and RSU/option vesting), ratification of BDO USA as auditor, approval of the 2026 Equity Incentive Plan and Employee Stock Purchase Plan, and authorization to adjourn the meeting. All matters were approved.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-07-07
Item 8.01
Following stockholder approval, Series C Preferred Stock automatically converted into common stock, and Series D Preferred Stock was voluntarily converted into 4,752,244 shares of common stock, increasing common share count to 27,635,745 shares outstanding with additional Series D convertible into 28,929,592 shares. These conversions materially dilute existing common shareholders' ownership and voting power.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-07
Item 1.01
NorthStrive Defense Tech, a wholly owned subsidiary of PMGC Holdings, entered into an exclusive license agreement for aerospace and defense technologies covering U.S. Patent No. 12,291,334 and associated know-how. While Item 1.01 typically covers M&A activity, this is a material strategic licensing arrangement that grants exclusive rights to develop and commercialize products in a defined field, with ongoing royalty obligations and diligence milestones. This is a material operational/strategic contract rather than a traditional acquisition or merger, making operational_other the most appropriate classification.
View raw filing on EDGAR →
8-K
M&A activity
confidence 97%
filed 2026-07-07
Item 2.01
House of Doge Inc. completed its merger with Brag House Holdings, Inc. (formerly NASDAQ: TBH) on June 30, 2026, resulting in a material change of control. The combined company was renamed House of Doge Inc., began trading under ticker 'HODO' on Nasdaq on July 1, 2026, with former HOD stockholders owning approximately 90.66% of issued and outstanding shares (83.32% on a fully diluted basis).
View raw filing on EDGAR →
6-K
Exec appointment
confidence 92%
filed 2026-07-07
EX-99.1
The press release announces three material executive and board leadership appointments: Tulani Sikwila as Chairman (in addition to CEO), Wendy Luhabe as Independent Non-Executive Director and Lead Independent Director, and Sphe Mchunu as Chief Financial Officer. These are discrete appointments of named executives and directors to key governance and operational roles, with Mchunu's transition from General Counsel to CFO being particularly significant for financial leadership during the company's growth phase and mine restart execution.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-07
Item 8.01
The disclosure centers on a non-binding letter of intent from Elko Heat Company to provide up to $40 million in joint development capital to support ACRG's pursuit of a BLM Solar Energy Zone competitive lease and solar development at the Millers Property in Nevada. While this involves capital commitment, it is explicitly non-binding and subject to multiple closing conditions (due diligence, investment committee approval, BLM authorization, definitive documentation). The event is primarily operational/strategic—a partnership and development opportunity—rather than a binding financial obligation (debt_issuance) or M&A activity. The materiality is high given the $40 million capital commitment and strategic importance to the company's energy infrastructure thesis, though the non-binding nature and contingencies temper certainty.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-07
Item 5.02
Chi Special Acquisition Corp. appointed two new directors, Chung Fu Wing and Shangwei Chen, effective June 2, 2026, to fill board vacancies. The appointments include detailed biographical information and represent a material change to board composition.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-07-07
EX-99.1
The Company received a Nasdaq notification dated July 1, 2026, that it failed to maintain the minimum bid price of US$1.00 per share required under Nasdaq Listing Rule 5550(a)(2). The Company has 180 calendar days (until December 28, 2026) to regain compliance or faces potential delisting. This is a classic delisting-risk disclosure under Item 3.01 equivalent, materially affecting the registrant's continued listing status.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-07
Item 2.01
CareDx completed two material M&A transactions: (1) sale of CareDx AB and lab products business to Eurobio Scientific for $171.7 million cash on June 30, 2026, and (2) acquisition of Naveris, Inc. for $161.8 million cash plus up to $100 million in contingent consideration on July 1, 2026. These transactions materially reshape CareDx's business portfolio by divesting its European lab products business while acquiring a high-growth specialty oncology diagnostics platform (NavDx) that expands the addressable market to $12+ billion.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-07
Item 2.01
The filing discloses the completed sale of the 357-room Marriott Fremont Silicon Valley hotel for $53.0 million in cash on July 1, 2026, pursuant to an Agreement of Purchase and Sale dated June 19, 2026. This is a material disposition of a hotel asset by Ashford Hospitality Trust, a REIT, and is properly classified under Item 2.01 (Completion of Acquisition or Disposition of Assets). The transaction is material to investors as it represents a significant reduction in the company's asset base and includes pro forma financial statements showing the removal of the property's revenue and expenses.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-07
Item 5.02
Jerome T. Upton, the Company's Executive Vice President and Chief Financial Officer, has been appointed Interim President and Chief Executive Officer effective July 7, 2026. While the filing also discloses that CEO Thomas J. McInerney is taking a temporary leave of absence for health reasons, the principal disclosed action is Upton's appointment to the interim CEO role. This is material as it represents a change in the principal executive officer position, even though it is temporary and the incumbent CEO is on leave rather than departing permanently.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-07-07
EX-99.1
This is a news release announcing the voting results from DeFi Technologies' 2026 Annual and Special Meeting of shareholders held on June 29, 2026. The disclosure reports detailed election results for six director nominees, approval of auditors (92.276% in favour), approval of a share consolidation (73.271% in favour), approval of an Amendment to By-Law No. 1 (90.420% in favour), and approval of an Advance Notice By-Law No. 2 (64.279% in favour). These are material shareholder votes that affect governance and capital structure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-07-07
Item 5.07
This is a clear disclosure of shareholder vote results from a Special Meeting held on July 7, 2026. The filing reports the final voting tallies on Proposal 1 to renew authorization for the Company to sell shares below net asset value, with specific vote counts (For: 277,640,199; Against: 63,873,735; Abstained: 7,460,523). This is a material governance event affecting the Company's capital-raising authority and is properly classified under Item 5.07.
View raw filing on EDGAR →
6-K
Debt Issuance
confidence 95%
filed 2026-07-07
The 6-K furnishes a closing notice for the public offering and issuance of R$ 1,000,000,000.00 (one billion reais) in simple debentures (non-convertible bonds) by AXIA Energia S.A., the 9th issuance of such debentures. The document confirms completion of the offering on June 15, 2026, with 1,000,000 debentures subscribed and paid in. This constitutes creation of a new direct financial obligation and is material to investors assessing the registrant's capital structure and leverage.
View raw filing on EDGAR →
8-K
Legal Other
confidence 85%
filed 2026-07-07
Item 8.01
The disclosure centers on an FDA Warning Letter issued to IMS (a subsidiary) on July 2, 2026, citing CGMP violations at its South El Monte manufacturing facility. This is a regulatory enforcement action that could materially impact the company's ability to manufacture and distribute products. While the Warning Letter does not currently direct cessation of production, the company acknowledges uncertainty about FDA satisfaction with remediation efforts and the possibility of "additional regulatory or legal action" without further notice, creating material regulatory and operational risk.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-07
Item 8.01
Axos Financial entered into a definitive agreement to acquire Arc Technologies, Inc., a financial technology platform. This is a material acquisition disclosed under Item 8.01 (Other Events). Although the company states the transaction is "not expected to have a material impact to results of operations or financial condition," the entry into a definitive agreement for an acquisition is itself a material event that would affect a reasonable investor's assessment of the registrant's strategic direction and capital deployment. The press release emphasizes Arc's AI capabilities, technology platform, and strategic fit with Axos' digital banking strategy.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-07-07
Item 2.03
The Federal Home Loan Bank of Des Moines discloses the creation of direct financial obligations through the issuance of consolidated obligation bonds and discount notes. Schedule A lists specific debt securities committed to be issued on trade dates in July 2026, with principal amounts totaling approximately $135 million across multiple bond tranches with varying maturities (2028–2036), coupons (4.50%–5.10%), and call features. This is a classic debt issuance disclosure under Item 2.03, material to the Bank's capital structure and funding operations.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-07-07
Item 2.03
The filing discloses the creation of direct financial obligations through the issuance of consolidated obligation bonds and discount notes by the Federal Home Loan Bank of Topeka. Schedule A details four specific debt issuances with trade dates in July 2026, totaling approximately $835 million in principal across fixed-rate and variable-rate instruments with maturities ranging from 2026 to 2031. This is a classic debt_issuance event under Item 2.03, material to investors assessing the registrant's capital structure and funding activities.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-07-07
Item 2.03
The filing discloses the creation of direct financial obligations through the issuance of consolidated obligation bonds and discount notes by the Federal Home Loan Bank of Pittsburgh. Schedule A itemizes six specific debt issuances with trade dates in July 2026, ranging from $5 million to $500 million in principal amount, with maturities from 2027 to 2041. This is a classic debt_issuance event under Item 2.03, material to investors assessing the registrant's capital structure and financial obligations.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-07-07
Item 2.03
The filing discloses the creation of direct financial obligations through the issuance of consolidated obligations (bonds and discount notes) by the Federal Home Loan Bank of Boston. Schedule A details four specific debt issuances with trade dates in July 2026, totaling approximately $640 million in principal, with maturity dates ranging from October 2026 to July 2029. This is a classic debt_issuance event under Item 2.03, disclosing new direct financial obligations created by the registrant.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-07-07
Item 2.03
The filing discloses the issuance of consolidated obligation bonds totaling $475 million (125M + 350M) by the Federal Home Loan Bank of Atlanta on trade date 7/1/2026, settling 7/6/2026 with maturity 10/6/2026. This represents a direct creation of financial obligations under Item 2.03, and the Bank explicitly states that "consolidated obligations issuance is material to the Bank." The detailed Schedule A provides specific terms including CUSIP, settlement, maturity, and rate structure for these debt securities.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-07-07
Item 2.03
The filing discloses the Federal Home Loan Bank of Indianapolis becoming the primary obligor on consolidated obligation bonds with a par value of $10,000,000, maturing 7/2/2031 at a 4.360% coupon, settled on 7/7/2026. This is a direct creation of a financial obligation under Item 2.03, constituting a debt issuance. The disclosure includes specific bond terms (CUSIP, maturity date, coupon rate, call provisions), which are hallmarks of debt creation disclosures.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-07-07
Item 2.03
The filing discloses the creation of direct financial obligations through the issuance of consolidated obligation bonds by the Federal Home Loan Bank of Dallas. Schedule A details two bond issuances with trade dates of 7/1/2026, totaling $30 million in par amount, with maturity dates in 2028 and 2030 respectively. This is a routine debt issuance disclosure under Item 2.03, which is material to investors as it represents new financial obligations of the registrant.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 75%
filed 2026-07-07
Item 8.01
The disclosure centers on shareholder approval of a dividend waiver aggregating up to $1.27 per share over twelve months. While technically a waiver (non-declaration) rather than a declaration, the event is material to investors as it affects capital allocation and shareholder returns. The 59% voting threshold and 97% approval rate indicate significant shareholder engagement on a capital decision. The MHC's 81% control and pending Federal Reserve approval add governance and regulatory dimensions, but the core event is the dividend decision itself.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-07-07
EX-99.1
This press release announces receipt of official FDA End-of-Phase 2 meeting minutes confirming a registrational pathway for ATH434 in Multiple System Atrophy, including FDA agreement on Phase 3 trial design and the possibility of approval based on a single pivotal trial plus confirmatory evidence. This is a material regulatory and clinical development milestone that advances the company's lead drug candidate toward potential NDA filing, but it is not a discrete event type in the taxonomy (not M&A, not an earnings release, not an executive change, not a restatement or going-concern issue). It represents a significant operational/strategic advancement in the drug development program that would affect a reasonable investor's assessment of the company's prospects.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-07
Item 8.01
Vaxart announced topline 12-month safety data from a Phase 2b clinical trial of its oral COVID-19 vaccine candidate, showing no vaccine-related serious adverse events or sustained Grade 3+ adverse events in either arm. This is a material clinical milestone for a clinical-stage biotech company, but it does not fit the specific categories of earnings_release (no financial results), material_litigation, or other named event types. The disclosure represents a significant operational/clinical development that would affect investor assessment of the company's vaccine program progress.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-07
Item 8.01
The filing discloses the completion of a merger between Envirotech Vehicles and Azio AI Corporation, closed on July 2, 2026. The press release explicitly states "the successful completion of its merger with Azio AI Corporation" and describes the transaction structure, merger consideration (2,655,157 shares of common stock and 973,450 shares of preferred stock), and the combined company's strategic pivot to AI infrastructure. This is a material acquisition that fundamentally transforms the registrant's business and capital structure.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-07-07
Item 7.01
BIO-key's disclosure announces the reinstatement of trading on Nasdaq Capital Market following a June 16th hearing where the Nasdaq Hearings Panel determined the Company "has regained compliance with the continued listing standards, including minimum bid price and SEC filing requirements." This directly addresses a delisting risk event—the company had previously been subject to a trading halt due to non-compliance with listing standards and has now resolved that issue. The materiality is clear: trading suspension and reinstatement materially affect investor access to the stock and the company's market standing.
View raw filing on EDGAR →
8-K
Exec departure
confidence 85%
filed 2026-07-07
Item 5.02
Lori M. Toomey, a Board member and Executive Committee member, has determined not to stand for re-election at the 2027 annual meeting, constituting a planned departure from her director role.
View raw filing on EDGAR →
8-K
Covenant Breach
confidence 72%
filed 2026-07-07
Item 7.01
The Toomey Directors' decision not to extend or renew the Toomey Loan (maturing December 31, 2026, with $365,000 principal and $9,191 accrued interest) creates a material liquidity crisis, with risk of cascading defaults on senior secured debt if the Company cannot refinance the obligation.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-07-07
Aptera announced receipt of an EPA Certificate of Conformity for its 2026 Launch Edition vehicle on June 18, 2026. The filing describes this as "an important federal emissions compliance milestone" and "one of the two primary federal certifications required before a vehicle can be legally sold in the United States." This is a material operational and regulatory milestone for a pre-revenue automotive manufacturer advancing toward commercialization, though it does not fit the specific categories of earnings, M&A, impairment, litigation, or other named event types.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 98%
filed 2026-07-07
EX-99.1
The exhibit is a press release announcing the appointment of Arie Goor as Chief Financial Officer of Core AI Holdings, effective July 1, 2026. The disclosure explicitly states "Core AI Holdings Appoints Arie Goor as Chief Financial Officer" and provides detailed background on his qualifications and prior experience. This is a clear executive appointment of a named officer to a material C-suite position, which would affect a reasonable investor's assessment of the company's leadership and financial management capabilities.
View raw filing on EDGAR →
8-K
Earnings release
confidence 92%
filed 2026-07-07
Item 8.01
The filing discloses quarterly financial results for Q2 2026 in a press release format (Exhibit 99.1), reporting "greater than 100% growth in revenue and new customers" compared to Q1 2026. This is a material earnings disclosure showing significant commercial traction following the LIBERTY System's Full Market Release in April 2026, including expansion of sales territories and entry into federal healthcare systems.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-07
The filing discloses the completion of a material disposition: on June 30, 2026, Glimpse Group sold all membership interests in Glimpse Learning, LLC (a wholly-owned subsidiary) to Glimpse Learning, Inc. pursuant to a Master Purchase Agreement. The transaction involves transfer of a business unit with associated intellectual property, technology, and contracts, with consideration including equity in the buyer (19.99% interest), ongoing royalty payments, and assumption of liabilities. Item 1.01 and Item 2.01 explicitly document entry into and completion of this material asset disposition.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-07
The filing discloses a press release announcing significant commercial sales acceleration for CyPath® Lung with over 200% year-over-year growth and 30% sequential growth, along with expansion metrics (155% increase in physician offices ordering). While this is a business milestone announcement, it does not fit the specific earnings_release category (which typically reports comprehensive quarterly financial results) but rather represents an operational/commercial milestone. The material growth metrics and market expansion data would affect a reasonable investor's assessment of the company's commercial trajectory and product adoption.
View raw filing on EDGAR →
8-K
Auditor Change
confidence 92%
filed 2026-07-07
The filing discloses under Item 4.01 that the Company's principal auditor BCRG had its attest business acquired by Simon & Edward LLP (S&E), and the Company will continue receiving audit services from the combined firm. Although technically a business acquisition rather than a resignation or dismissal, this constitutes a material change in the registrant's independent accountant, as the audit function transitions from BCRG to S&E. The disclosure includes the required representations that BCRG's prior audit reports contained no disclaimers, adverse opinions, or disagreements.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 75%
filed 2026-07-07
Item 2.03
The filing discloses creation of new direct financial obligations through three convertible promissory notes dated June 30, 2026, issued to CPC Sponsor Opportunities I, LP, CPC Sponsor Opportunities I (Parallel), LP, and NovoCG, LLC, along with an omnibus note exchange and debt conversion agreement. While Item 9.01 lists exhibits rather than Item 2.03 directly, the substance reflects debt issuance activity involving convertible debt instruments and debt restructuring.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-07-07
Item 2.03
The Company entered into an amended and restated SEPA with Yorkville on June 26, 2026, and issued a $2.0 million Promissory Note (with 5% original issue discount, yielding ~$1.8 million in gross proceeds) on June 30, 2026. The Promissory Note is a direct financial obligation bearing 5% interest (escalating to 18% upon default), maturing June 30, 2027, and convertible into Class A common stock. This constitutes creation of a new direct financial obligation under Item 2.03, with an additional $2.0 million Promissory Note to follow upon SEC registration statement effectiveness. The dilutive conversion feature and material terms make this a significant capital-raising event.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-07-07
The 6-K discloses a private placement of 331,753,557 ordinary shares and 995,260,671 warrants for US$700 million, closed on July 3, 2026. This is a material unregistered equity issuance that dilutes existing shareholders and raises substantial capital. The transaction is explicitly described as a private placement under a Securities Purchase Agreement, fitting the definition of dilutive_issuance.
View raw filing on EDGAR →
8-K
Governance Other
confidence 85%
filed 2026-07-07
Item 3.03
Tecnoglass completed a change of incorporation jurisdiction from the Cayman Islands to Florida effective July 7, 2026, resulting in a material modification of shareholder rights. Ordinary shares became registered common stock under Florida law, with substantive differences in governance rights between Cayman and Florida law.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-07
XMax Inc. entered into Securities Purchase Agreements on July 1, 2026, to sell 434,600 shares of common stock at $8.454 per share for an aggregate offering price of $3,674,108.40 in a private placement to non-U.S. investors under Regulation S. This is a classic unregistered equity issuance disclosed under Item 1.01 and Item 3.02, representing dilutive capital raising activity material to investors assessing ownership and equity structure.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 85%
filed 2026-07-07
NextNRG entered into a Merchant Cash Advance (MCA) agreement with Avanza Capital on June 30, 2026, creating a direct financial obligation. The Company received $940,000 in net proceeds in exchange for selling $1,499,900 of future receivables and committing to remit 25% of daily settlements until the purchased amount is delivered. While structured as a receivables purchase rather than traditional debt, the MCA functions as a secured financing obligation with fixed periodic payments ($62,496 estimated), security interests in substantially all assets, and default provisions—characteristics of debt issuance. The CEO personally guaranteed performance, underscoring materiality to investors assessing the Company's capital structure and financial obligations.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-07-07
The filing discloses Item 5.07 results from Mama's Creations' Annual Meeting of Stockholders held on July 2, 2026. The company reports voting outcomes for three proposals: election of five board directors (with specific vote tallies for each nominee), ratification of UHY LLP as independent auditor, and advisory approval of executive compensation. These are standard shareholder vote results that materially inform investors about governance and board composition.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-07
Item 2.01
The filing discloses the completion of a merger on June 30, 2026, in which Aeternum Health LLC merged with and into Shorepower Technologies, Inc., with Shorepower as the surviving entity. The merger resulted in a change of control, with Paul Mann receiving 49 million shares (51% ownership) and 2 million Series B preferred shares with enhanced voting power. The company also changed its name to Aeternum Health, Inc. and shifted its business focus from transportation electrification to critical minerals mining and longevity products. This is a material acquisition/change of control event under Item 2.01.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-07-07
The filing discloses entry into an Amended and Restated Senior Secured Convertible Note and Amended and Restated Loan Agreement on June 30, 2026, creating a direct financial obligation of $1,971,000 principal amount with $1,460,000 in proceeds. Item 1.01 and Item 2.03 both address this debt creation, which is a material financial obligation requiring 8-K disclosure under Item 2.03.
View raw filing on EDGAR →